PPGN Share Price Performance
CHF 0
-25.50 (-100.00%)
Price CHF 0
Fair ValueCHF 43.88
Share Pricen/a
PolyPeptide Group AG Stock Price
- 4 Narratives written by author
- 0 Comments on narratives written by author
- 8 Fair Values set on narratives written by author
PPGN Community Narratives
AN
Fair Value
·Fair Value CHF 43.88 Fairly Valued intrinsic discount
Metabolic Peptide Demand And New Capacity Will Support Stronger Long Term Earnings Potential
0users have liked this narrative
0users have commented on this narrative
1users have followed this narrative
AN
Fair Value
·Fair Value CHF 38.45 14.4% overvalued intrinsic discount
Metabolics Shift And New Capacity Will Support Long Term Peptide CDMO Opportunity
0users have liked this narrative
0users have commented on this narrative
1users have followed this narrative
PK
Fair Value
·Fair Value CHF 33.1 32.9% overvalued intrinsic discount
Biotech longerterm bet
0users have liked this narrative
0users have commented on this narrative
0users have followed this narrative
PolyPeptide Group
32.9% overvalued intrinsic discount
Biotech longerterm bet
View narrativePK
Published 14 Aug 2024
PolyPeptide Group
14.4% overvalued intrinsic discount
Metabolics Shift And New Capacity Will Support Long Term Peptide CDMO Opportunity
View narrativeAN
Updated 26 Jun
PolyPeptide Group
70.7% overvalued intrinsic discount
Metabolic Capacity Expansion And Peptide Outsourcing Shifts Will Face Headwinds Yet Ultimately Support Upside
View narrativeAN
Updated 10 Jul
PolyPeptide Group
Fairly Valued intrinsic discount
Metabolic Peptide Demand And New Capacity Will Support Stronger Long Term Earnings Potential
View narrativeAN
Published 9 Jan
Trending Discussion
No trending discussion available.
Recently Updated Narratives
PK
Biotech longerterm bet
Fair Value: CHF 33.1 32.9% overvalued intrinsic discount
0 fair values setusers have set this as their fair value
0 commentsusers have commented on this narrative
0 likesusers have liked this narrative
AN
PPGN: Takeover Hopes Will Test Sustainability Of Recent Share Price Surge
Fair Value: CHF 25.77 70.7% overvalued intrinsic discount
1 fair value setusers have set this as their fair value
0 commentsusers have commented on this narrative
0 likesusers have liked this narrative
AN
PPGN: Raised Price Views Will Likely Overstate Takeover Hopes
Fair Value: CHF 38.45 14.4% overvalued intrinsic discount
1 fair value setusers have set this as their fair value
0 commentsusers have commented on this narrative
0 likesusers have liked this narrative
Snowflake Analysis
PolyPeptide Group AG Key Details
Last Reported Earnings
Jun 30, 2026
Next Reporting Earnings
Mar 09, 2027
- 0.44
- 22.86%
- 3.15%
- 36.9%
About PPGN
- Founded
- 1952
- Employees
- 1460
- CEO
- WebsiteView website
PolyPeptide Group AG operates as a contract development and manufacturing company in Europe, the United States, Asia Pacific, and internationally. It develops and manufactures synthetic peptides used as active pharmaceutical ingredients or intermediates in therapeutic products. The company offers portfolio of drug therapies for metabolic diseases, including the GLP-1. It also provides generic peptides and peptides used in cosmetics, animal health, and medical devices, as well as development and analytical services. The company serves academic, pharmaceutical, and biotech companies. PolyPeptide Group AG was founded in 1952 and is headquartered in Baar, Switzerland. PolyPeptide Group AG is a subsidiary of Draupnir Holding B.V.
